Table 3. Predictive accuracy of various prostate cancer nomograms.
| Study | n | Patients | Cancer rate (%) | Validation | Mean age (year) | Median PSA (ng ml−1) | AUC for model (%) | AUC for PSA (%) | Increase in AUC vs. PSA alone (%) |
|---|---|---|---|---|---|---|---|---|---|
| PCPT15 | 5519 | CA (95.6%) | 21.9 | Internal | ≥55 | 1.5 | 70.2 | 67.8 | 2.4 |
| Hernandez et al.16 | 1108 | CA (85.0%) | 35.6 | NA | 63 | 5.4 | 66.7 | 61.9 | 4.8 |
| Suzuki et al.17 | 834 | Japanese | 28.9 | NA | 70 | 13.1 (mean) | 81.8 | 69.8 | 12.0 |
| Park et al.18 | 602 | Korean | 28.6 | NA | 66 | 6.77 | 72 | 66 | 6 |
| Garzotto et al.19 | 1239 | CA (93.5%) | 24.3 | Internal | 66 | 5.10 | 73 | 62 | 11 |
| Our model | 535 | Chinese | 44.8 | Internal | 72 | 17.8 | 84.8 | 79.7 | 5.1 |
Abbreviations: AUC, area under the curve; CA, Caucasian American; NA, not available; PCPT, Prostate Cancer Prevention Trial; PSA, prostate-specific antigen.